Hello Inside Raises €1.65m to Transform Women's Metabolic Health with CGM Data
Hello Inside, a metabolic health service using Continuous Glucose Monitoring (CGM) technology tailored for women, has secured €1.65 million in seed funding.
The round was led by Verge Fund, an international HealthTech venture capital firm, with backing from key players including DocMorris, Germany’s leading online pharmacy, and Kapa Ventures. Previous supporters such as Lea-Sophie Cramer (Amorelie), Martin Murray (Waterdrop), Eric Demuth (Bitpanda), along with 10xFounders, Simon Capital, and Miele Ventures, also participated.
Advancing Innovation in Women's Health
This funding marks a significant milestone for Hello Inside and its investors, particularly amidst the current economic challenges facing the FemTech industry. The investment highlights both the company’s potential and the need for continued innovation and development in a sector that has long been underfunded. Despite the global FemTech market being valued at $44 billion, only 4% of health tech funding in 2023 was allocated to it. This new investment aims to address the imbalance and fuel much-needed growth in women’s health solutions.
Scarlett Chen, the lead investor from Verge Fund, emphasized the importance of this investment: "We see enormous potential in Hello Inside, not only in terms of market opportunity but also in the positive impact it can have on women's health worldwide. The highly disciplined and performance-driven team has created one of the most engaging digital health apps globally. The unique combination of cutting-edge technology and the focus on women's specific health needs aligns perfectly with our mission at Verge HealthTech Fund."
Transformative Technology for Women's Health
Hello Inside’s platform combines third-party continuous glucose monitoring (CGM) with advanced AI to offer women deep insights into their metabolic health. By tracking and analysing key lifestyle factors – such as food, movement, stress, and sleep—the platform helps users make informed decisions about their wellbeing. It seamlessly integrates with popular health devices like the Oura Ring and Apple Health, creating a comprehensive health tracking system aimed at behaviour change.
Given the complexity and individuality of human metabolism, AI-driven analysis of metabolic data provides users with valuable understanding and a new perspective on their bodies. Since launching, the platform has seen positive engagement, with users averaging over 10 app interactions per day and 80% achieving their weight goals within 30 days.
Following this strong user response, Hello Inside aims to use its recent funding to further validate its engagement model through clinical trials and expand into the B2B space, cementing its position in the rapidly growing FemTech sector.
Mario Aichlseder, CEO of Hello Inside, highlights the unique value of the platform: "Attention is the key to behaviour change and positive health impact. By pairing this with the power of AI and the knowledge of our medical experts, we can offer women a profound understanding of their metabolic health. Our technology is not just about tracking data, but about providing actionable insights that lead to meaningful changes in health and wellness."
Hello Inside is poised to build on the recent successes of trailblazers like Oura and Clue as it continues its mission to support women on their metabolic health journeys. Despite the challenges faced in securing funding, the company's recent achievements, coupled with the rise of the first EU health unicorn, Flo, have turned the spotlight onto FemTech. With all eyes on this sector, Hello Inside anticipates that 2025 will bring even greater opportunities for growth and impact.